Serum bile acid profiles are associated with heart failure with preserved ejection fraction in patients with metabolic dysfunction‐associated fatty liver disease: An exploratory study
Aim To analyse the association between serum bile acid (BA) profile and heart failure (HF) with preserved ejection fraction (HFpEF) in patients with metabolic dysfunction‐associated fatty liver disease (MAFLD). Methods We enrolled 163 individuals with biopsy‐proven MAFLD undergoing transthoracic ech...
Saved in:
Published in | Diabetes, obesity & metabolism Vol. 26; no. 9; pp. 3684 - 3695 |
---|---|
Main Authors | , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Oxford, UK
Blackwell Publishing Ltd
01.09.2024
Wiley Subscription Services, Inc |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Aim
To analyse the association between serum bile acid (BA) profile and heart failure (HF) with preserved ejection fraction (HFpEF) in patients with metabolic dysfunction‐associated fatty liver disease (MAFLD).
Methods
We enrolled 163 individuals with biopsy‐proven MAFLD undergoing transthoracic echocardiography for any indication. HFpEF was defined as left ventricular ejection fraction >50% with at least one echocardiographic feature of HF (left ventricular diastolic dysfunction, abnormal left atrial size) and at least one HF sign or symptom. Serum levels of 38 BAs were analysed using ultra‐performance liquid chromatography coupled with tandem mass spectrometry.
Results
Among the 163 patients enrolled (mean age 47.0 ± 12.8 years, 39.3% female), 52 (31.9%) and 43 (26.4%) met the HFpEF and pre‐HFpEF criteria, and 38 serum BAs were detected. Serum ursodeoxycholic acid (UDCA) and hyocholic acid (HCA) species were lower in patients with HFpEF and achieved statistical significance after correction for multiple comparisons. Furthermore, decreases in glycoursodeoxycholic acid and tauroursodeoxycholic acid were associated with HF status.
Conclusions
In this exploratory study, specific UDCA and HCA species were associated with HFpEF status in adults with biopsy‐confirmed MAFLD. |
---|---|
AbstractList | Aim
To analyse the association between serum bile acid (BA) profile and heart failure (HF) with preserved ejection fraction (HFpEF) in patients with metabolic dysfunction‐associated fatty liver disease (MAFLD).
Methods
We enrolled 163 individuals with biopsy‐proven MAFLD undergoing transthoracic echocardiography for any indication. HFpEF was defined as left ventricular ejection fraction >50% with at least one echocardiographic feature of HF (left ventricular diastolic dysfunction, abnormal left atrial size) and at least one HF sign or symptom. Serum levels of 38 BAs were analysed using ultra‐performance liquid chromatography coupled with tandem mass spectrometry.
Results
Among the 163 patients enrolled (mean age 47.0 ± 12.8 years, 39.3% female), 52 (31.9%) and 43 (26.4%) met the HFpEF and pre‐HFpEF criteria, and 38 serum BAs were detected. Serum ursodeoxycholic acid (UDCA) and hyocholic acid (HCA) species were lower in patients with HFpEF and achieved statistical significance after correction for multiple comparisons. Furthermore, decreases in glycoursodeoxycholic acid and tauroursodeoxycholic acid were associated with HF status.
Conclusions
In this exploratory study, specific UDCA and HCA species were associated with HFpEF status in adults with biopsy‐confirmed MAFLD. To analyse the association between serum bile acid (BA) profile and heart failure (HF) with preserved ejection fraction (HFpEF) in patients with metabolic dysfunction-associated fatty liver disease (MAFLD).AIMTo analyse the association between serum bile acid (BA) profile and heart failure (HF) with preserved ejection fraction (HFpEF) in patients with metabolic dysfunction-associated fatty liver disease (MAFLD).We enrolled 163 individuals with biopsy-proven MAFLD undergoing transthoracic echocardiography for any indication. HFpEF was defined as left ventricular ejection fraction >50% with at least one echocardiographic feature of HF (left ventricular diastolic dysfunction, abnormal left atrial size) and at least one HF sign or symptom. Serum levels of 38 BAs were analysed using ultra-performance liquid chromatography coupled with tandem mass spectrometry.METHODSWe enrolled 163 individuals with biopsy-proven MAFLD undergoing transthoracic echocardiography for any indication. HFpEF was defined as left ventricular ejection fraction >50% with at least one echocardiographic feature of HF (left ventricular diastolic dysfunction, abnormal left atrial size) and at least one HF sign or symptom. Serum levels of 38 BAs were analysed using ultra-performance liquid chromatography coupled with tandem mass spectrometry.Among the 163 patients enrolled (mean age 47.0 ± 12.8 years, 39.3% female), 52 (31.9%) and 43 (26.4%) met the HFpEF and pre-HFpEF criteria, and 38 serum BAs were detected. Serum ursodeoxycholic acid (UDCA) and hyocholic acid (HCA) species were lower in patients with HFpEF and achieved statistical significance after correction for multiple comparisons. Furthermore, decreases in glycoursodeoxycholic acid and tauroursodeoxycholic acid were associated with HF status.RESULTSAmong the 163 patients enrolled (mean age 47.0 ± 12.8 years, 39.3% female), 52 (31.9%) and 43 (26.4%) met the HFpEF and pre-HFpEF criteria, and 38 serum BAs were detected. Serum ursodeoxycholic acid (UDCA) and hyocholic acid (HCA) species were lower in patients with HFpEF and achieved statistical significance after correction for multiple comparisons. Furthermore, decreases in glycoursodeoxycholic acid and tauroursodeoxycholic acid were associated with HF status.In this exploratory study, specific UDCA and HCA species were associated with HFpEF status in adults with biopsy-confirmed MAFLD.CONCLUSIONSIn this exploratory study, specific UDCA and HCA species were associated with HFpEF status in adults with biopsy-confirmed MAFLD. To analyse the association between serum bile acid (BA) profile and heart failure (HF) with preserved ejection fraction (HFpEF) in patients with metabolic dysfunction-associated fatty liver disease (MAFLD). We enrolled 163 individuals with biopsy-proven MAFLD undergoing transthoracic echocardiography for any indication. HFpEF was defined as left ventricular ejection fraction >50% with at least one echocardiographic feature of HF (left ventricular diastolic dysfunction, abnormal left atrial size) and at least one HF sign or symptom. Serum levels of 38 BAs were analysed using ultra-performance liquid chromatography coupled with tandem mass spectrometry. Among the 163 patients enrolled (mean age 47.0 ± 12.8 years, 39.3% female), 52 (31.9%) and 43 (26.4%) met the HFpEF and pre-HFpEF criteria, and 38 serum BAs were detected. Serum ursodeoxycholic acid (UDCA) and hyocholic acid (HCA) species were lower in patients with HFpEF and achieved statistical significance after correction for multiple comparisons. Furthermore, decreases in glycoursodeoxycholic acid and tauroursodeoxycholic acid were associated with HF status. In this exploratory study, specific UDCA and HCA species were associated with HFpEF status in adults with biopsy-confirmed MAFLD. AimTo analyse the association between serum bile acid (BA) profile and heart failure (HF) with preserved ejection fraction (HFpEF) in patients with metabolic dysfunction‐associated fatty liver disease (MAFLD).MethodsWe enrolled 163 individuals with biopsy‐proven MAFLD undergoing transthoracic echocardiography for any indication. HFpEF was defined as left ventricular ejection fraction >50% with at least one echocardiographic feature of HF (left ventricular diastolic dysfunction, abnormal left atrial size) and at least one HF sign or symptom. Serum levels of 38 BAs were analysed using ultra‐performance liquid chromatography coupled with tandem mass spectrometry.ResultsAmong the 163 patients enrolled (mean age 47.0 ± 12.8 years, 39.3% female), 52 (31.9%) and 43 (26.4%) met the HFpEF and pre‐HFpEF criteria, and 38 serum BAs were detected. Serum ursodeoxycholic acid (UDCA) and hyocholic acid (HCA) species were lower in patients with HFpEF and achieved statistical significance after correction for multiple comparisons. Furthermore, decreases in glycoursodeoxycholic acid and tauroursodeoxycholic acid were associated with HF status.ConclusionsIn this exploratory study, specific UDCA and HCA species were associated with HFpEF status in adults with biopsy‐confirmed MAFLD. |
Author | Huang, Chen‐Xiao Zheng, Ming‐Hua Tian, Na Xu, Cui‐Fang Shapiro, Michael D. Chen, Li‐Li Zhou, Xiao‐Dong Targher, Giovanni Ni, Yan Chen, Qin‐Fen Lip, Gregory Y. H. Byrne, Christopher D. Xiao, Tie |
Author_xml | – sequence: 1 givenname: Xiao‐Dong orcidid: 0000-0002-8534-0818 surname: Zhou fullname: Zhou, Xiao‐Dong organization: The First Affiliated Hospital of Wenzhou Medical University – sequence: 2 givenname: Cui‐Fang surname: Xu fullname: Xu, Cui‐Fang organization: National Clinical Research Center for Child Health – sequence: 3 givenname: Qin‐Fen orcidid: 0000-0001-6596-5004 surname: Chen fullname: Chen, Qin‐Fen organization: Wenzhou Medical University – sequence: 4 givenname: Michael D. surname: Shapiro fullname: Shapiro, Michael D. organization: Wake Forest University School of Medicine – sequence: 5 givenname: Gregory Y. H. orcidid: 0000-0002-7566-1626 surname: Lip fullname: Lip, Gregory Y. H. organization: Aalborg University – sequence: 6 givenname: Li‐Li surname: Chen fullname: Chen, Li‐Li organization: The First Affiliated Hospital of Wenzhou Medical University – sequence: 7 givenname: Giovanni orcidid: 0000-0002-4325-3900 surname: Targher fullname: Targher, Giovanni organization: IRCCS Sacro Cuore – Don Calabria Hospital – sequence: 8 givenname: Christopher D. orcidid: 0000-0001-6322-7753 surname: Byrne fullname: Byrne, Christopher D. organization: University Hospital Southampton, University of Southampton, Southampton General Hospital – sequence: 9 givenname: Na orcidid: 0009-0007-3543-8036 surname: Tian fullname: Tian, Na organization: The First Affiliated Hospital of Wenzhou Medical University – sequence: 10 givenname: Tie orcidid: 0009-0007-5630-8759 surname: Xiao fullname: Xiao, Tie organization: The First Affiliated Hospital of Wenzhou Medical University – sequence: 11 givenname: Chen‐Xiao orcidid: 0009-0008-5427-5401 surname: Huang fullname: Huang, Chen‐Xiao organization: The First Affiliated Hospital of Wenzhou Medical University – sequence: 12 givenname: Yan orcidid: 0000-0003-1779-7266 surname: Ni fullname: Ni, Yan email: yanni617@zju.edu.cn organization: National Clinical Research Center for Child Health – sequence: 13 givenname: Ming‐Hua orcidid: 0000-0003-4984-2631 surname: Zheng fullname: Zheng, Ming‐Hua email: zhengmh@wmu.edu.cn organization: Key Laboratory of Diagnosis and Treatment for the Development of Chronic Liver Disease in Zhejiang Province |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38874096$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kctu1TAQhi1URC-w4AWQJTZlkdaXXNlV5SoVdQGso4k9Vn2UxMF2WrLjEXidvk6fBJ-TglAl8Ma_x9-Mrf8_JHujG5GQ55yd8LROtRtOeFGx5hE54HkpMy5FubfTIqsbJvbJYQgbxlgu6-oJ2Zd1XeWsKQ_I7Wf080A72yMFZTWdvDPpECj4VAnBKQsRNb2x8YpeIfhIDdh-Tre70uQxoL9OBG5QRetGajyswo50gmhxjGGFB4zQud4qqpdg5nGH3f34-dc7BmJcaG-v0VNtA0LA1_RspPh96p2H6PxCQ5z18pQ8NtAHfHa_H5Gv795-Of-QXVy-_3h-dpEpWcgmk8KwXEihuBZaJWMK3Yi86UwJiiHjSvCSN6pidWEAQWLZgUHJjYKktJBH5Hidm5z5NmOI7WCDwr6HEd0cWsnKuip4wcuEvnyAbtzsx_S7RNVVw-tabqkX99TcDajbydsB_NL-DiUBr1ZAeReCR_MH4azdBt6mwNtd4Ik9fcAqG2Fra_Qppv913KSYl3-Pbt9cflo7fgGVq8Hx |
CitedBy_id | crossref_primary_10_1080_07853890_2024_2442535 crossref_primary_10_1016_j_cca_2024_120004 crossref_primary_10_3390_biom14070841 crossref_primary_10_1097_CP9_0000000000000106 crossref_primary_10_3390_ijms26052242 crossref_primary_10_1002_ehf2_15097 |
Cites_doi | 10.1007/s13238-020-00804-9 10.1002/ejhf.2333 10.1016/j.bbadis.2017.12.039 10.1016/j.cmet.2020.11.017 10.1007/s12072-023-10543-8 10.1161/JAHA.121.021654 10.1002/hep.28707 10.1111/1755-5922.12462 10.1016/j.cardfail.2017.06.007 10.1002/hep.28431 10.3390/antiox11091822 10.1016/S0140-6736(14)61933-4 10.3390/biom8040159 10.1002/hep.28890 10.1111/jgh.14894 10.1111/dom.15014 10.1002/cbf.3303 10.1016/j.immuni.2016.10.009 10.1161/JAHA.123.032997 10.1111/dom.15016 10.1038/s41575-023-00846-4 10.1007/s11906-023-01242-8 10.1016/j.jacc.2021.11.007 10.1016/j.scib.2024.01.006 10.1161/JAHA.119.014279 10.1186/s12933-022-01697-0 10.1007/s00392-023-02371-5 10.1097/HJH.0000000000002716 10.21037/hbsn-22-421 10.1038/s41586-019-1865-0 |
ContentType | Journal Article |
Copyright | 2024 John Wiley & Sons Ltd. |
Copyright_xml | – notice: 2024 John Wiley & Sons Ltd. |
DBID | AAYXX CITATION NPM 7T5 7TK H94 K9. 7X8 |
DOI | 10.1111/dom.15709 |
DatabaseName | CrossRef PubMed Immunology Abstracts Neurosciences Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
DatabaseTitle | CrossRef PubMed AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Neurosciences Abstracts MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic PubMed AIDS and Cancer Research Abstracts |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1463-1326 |
EndPage | 3695 |
ExternalDocumentID | 38874096 10_1111_dom_15709 DOM15709 |
Genre | researchArticle Journal Article |
GrantInformation_xml | – fundername: High Level Creative Talents from Department of Public Health in Zhejiang Province funderid: S2032102600032 – fundername: Southampton National Institute for Health and Care Research (NIHR) Biomedical Research Centre funderid: NIHR203319 – fundername: School of Medicine, University of Verona – fundername: National Natural Science Foundation of China funderid: 82070588; 82370577 – fundername: Southampton National Institute for Health and Care Research (NIHR) Biomedical Research Centre grantid: NIHR203319 – fundername: High Level Creative Talents from Department of Public Health in Zhejiang Province grantid: S2032102600032 – fundername: National Natural Science Foundation of China grantid: 82070588 – fundername: National Natural Science Foundation of China grantid: 82370577 |
GroupedDBID | --- .3N .GA .GJ .Y3 05W 0R~ 10A 1OC 29F 31~ 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAKAS AAMNL AANHP AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACRPL ACSCC ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZCM ADZMN ADZOD AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFPM AFGKR AFPWT AFWVQ AFZJQ AHBTC AHMBA AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBS EJD EMOBN ESX EX3 F00 F01 F04 F5P FEDTE FUBAC G-S G.N GODZA H.X HF~ HGLYW HVGLF HZI HZ~ IHE IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OVD P2W P2X P2Z P4B P4D PQQKQ Q.N Q11 QB0 R.K ROL RX1 SUPJJ TEORI UB1 W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WRC WVDHM WXI WXSBR XG1 YFH ZZTAW ~IA ~KM ~WT AAYXX AEYWJ AGHNM AGQPQ AGYGG CITATION NPM 7T5 7TK AAMMB AEFGJ AGXDD AIDQK AIDYY H94 K9. 7X8 |
ID | FETCH-LOGICAL-c3539-32f04232c1d2dc1325d9249bf6ac0e01c21619c7085faea3e6bafe31fca6bad23 |
IEDL.DBID | DR2 |
ISSN | 1462-8902 1463-1326 |
IngestDate | Fri Jul 11 11:38:44 EDT 2025 Sun Jul 13 03:20:33 EDT 2025 Thu Apr 03 07:07:43 EDT 2025 Thu Apr 24 23:10:27 EDT 2025 Tue Jul 01 02:58:18 EDT 2025 Wed Jan 22 17:17:51 EST 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 9 |
Keywords | metabolic dysfunction‐associated fatty liver disease heart failure with preserved ejection fraction bile acids profile |
Language | English |
License | 2024 John Wiley & Sons Ltd. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c3539-32f04232c1d2dc1325d9249bf6ac0e01c21619c7085faea3e6bafe31fca6bad23 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ORCID | 0000-0002-8534-0818 0000-0001-6596-5004 0000-0002-4325-3900 0009-0007-3543-8036 0000-0002-7566-1626 0000-0003-4984-2631 0009-0007-5630-8759 0000-0003-1779-7266 0000-0001-6322-7753 0009-0008-5427-5401 |
PMID | 38874096 |
PQID | 3087918836 |
PQPubID | 1006516 |
PageCount | 12 |
ParticipantIDs | proquest_miscellaneous_3068751516 proquest_journals_3087918836 pubmed_primary_38874096 crossref_primary_10_1111_dom_15709 crossref_citationtrail_10_1111_dom_15709 wiley_primary_10_1111_dom_15709_DOM15709 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | September 2024 |
PublicationDateYYYYMMDD | 2024-09-01 |
PublicationDate_xml | – month: 09 year: 2024 text: September 2024 |
PublicationDecade | 2020 |
PublicationPlace | Oxford, UK |
PublicationPlace_xml | – name: Oxford, UK – name: England – name: Oxford |
PublicationTitle | Diabetes, obesity & metabolism |
PublicationTitleAlternate | Diabetes Obes Metab |
PublicationYear | 2024 |
Publisher | Blackwell Publishing Ltd Wiley Subscription Services, Inc |
Publisher_xml | – name: Blackwell Publishing Ltd – name: Wiley Subscription Services, Inc |
References | 2023; 14 2023; 11 2023; 12 2023; 17 2017; 65 2015; 385 2017; 23 2022; 24 2020; 35 2022; 21 2024; 13 2022; 145 2018; 8 2021; 10 2018; 1864 2023; 25 2021; 12 2021; 33 2021; 39 2017; 35 2020; 9 2016; 64 2022; 79 2020; 577 2024; 21 2024; 113 2022; 11 2024; 69 2024; 29 2018; 36 2016; 45 e_1_2_10_23_1 e_1_2_10_24_1 e_1_2_10_21_1 e_1_2_10_22_1 e_1_2_10_20_1 Zhou XD (e_1_2_10_16_1) 2024; 13 e_1_2_10_2_1 e_1_2_10_18_1 e_1_2_10_3_1 e_1_2_10_19_1 Yu W (e_1_2_10_35_1) 2023; 11 e_1_2_10_6_1 e_1_2_10_5_1 e_1_2_10_17_1 e_1_2_10_8_1 e_1_2_10_14_1 e_1_2_10_7_1 e_1_2_10_15_1 e_1_2_10_12_1 Zhang S (e_1_2_10_26_1) 2023; 14 e_1_2_10_13_1 e_1_2_10_34_1 e_1_2_10_10_1 e_1_2_10_33_1 e_1_2_10_11_1 e_1_2_10_32_1 e_1_2_10_31_1 e_1_2_10_30_1 Miao L (e_1_2_10_4_1) 2024; 29 e_1_2_10_29_1 Heidenreich PA (e_1_2_10_9_1) 2022; 145 e_1_2_10_27_1 e_1_2_10_28_1 e_1_2_10_25_1 |
References_xml | – volume: 29 start-page: S1043 year: 2024 end-page: S2760 article-title: Current status and future trends of the global burden of MASLD publication-title: Trends Endocrinol Metab – volume: 69 start-page: 850 year: 2024 end-page: 852 article-title: From HFpEF to "metabolic (dysfunction)‐associated HFpEF": time to act publication-title: Sci Bull (Beijing) – volume: 23 start-page: 666 year: 2017 end-page: 671 article-title: Increased secondary/primary bile acid ratio in chronic heart failure publication-title: J Card Fail – volume: 24 start-page: 4 year: 2022 end-page: 131 article-title: 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the heart failure association (HFA) of the ESC publication-title: Eur J Heart Fail – volume: 21 start-page: 46 year: 2024 end-page: 56 article-title: Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease publication-title: Nat Rev Gastroenterol Hepatol – volume: 79 start-page: 180 year: 2022 end-page: 191 article-title: Risk of heart failure in patients with nonalcoholic fatty liver disease: JACC review topic of the week publication-title: J Am Coll Cardiol – volume: 35 start-page: 1057 year: 2020 end-page: 1064 article-title: Effect of PNPLA3 polymorphism on diagnostic performance of various noninvasive markers for diagnosing and staging nonalcoholic fatty liver disease publication-title: J Gastroenterol Hepatol – volume: 35 start-page: 453 year: 2017 end-page: 463 article-title: Ursodeoxycholic acid protects cardiomyocytes against cobalt chloride induced hypoxia by regulating transcriptional mediator of cells stress hypoxia inducible factor 1α and p53 protein publication-title: Cell Biochem Funct – volume: 65 start-page: 189 year: 2017 end-page: 201 article-title: Bile acid excess induces cardiomyopathy and metabolic dysfunctions in the heart publication-title: Hepatology – volume: 113 start-page: 761 year: 2024 end-page: 769 article-title: Clinical characteristics and prognosis of patients with hypertrophic cardiomyopathy and heart failure with preserved ejection fraction publication-title: Clin Res Cardiol – volume: 65 start-page: 813 year: 2017 end-page: 827 article-title: G‐protein‐coupled bile acid receptor plays a key role in bile acid metabolism and fasting‐induced hepatic steatosis in mice publication-title: Hepatology – volume: 21 start-page: 270 year: 2022 article-title: Metabolic dysfunction‐associated fatty liver disease and implications for cardiovascular risk and disease prevention publication-title: Cardiovasc Diabetol – volume: 11 start-page: 1822 year: 2022 article-title: NADPH oxidases in diastolic dysfunction and heart failure with preserved ejection fraction publication-title: Antioxidants (Basel) – volume: 17 start-page: 773 year: 2023 end-page: 791 article-title: An international multidisciplinary consensus statement on MAFLD and the risk of CVD publication-title: Hepatol Int – volume: 25 start-page: 13 issue: Suppl 1 year: 2023 end-page: 26 article-title: Epidemiological characteristics and management of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis in China: a narrative review publication-title: Diabetes Obes Metab – volume: 9 year: 2020 article-title: Longitudinal association of non‐alcoholic fatty liver disease with changes in myocardial structure and function: the CARDIA study publication-title: J Am Heart Assoc – volume: 577 start-page: 410 year: 2020 end-page: 415 article-title: Microbial bile acid metabolites modulate gut RORγ regulatory T cell homeostasis publication-title: Nature – volume: 39 start-page: 961 year: 2021 end-page: 969 article-title: Fatty liver index and left ventricular mass: prospective associations from two independent cohorts publication-title: J Hypertens – volume: 25 start-page: 1421 year: 2023 end-page: 1433 article-title: Nonalcoholic fatty liver disease from a primary care perspective publication-title: Diabetes Obes Metab – volume: 13 year: 2024 article-title: High‐sensitivity C‐reactive protein is associated with heart failure hospitalization in patients with metabolic dysfunction‐associated fatty liver disease and normal left ventricular ejection fraction undergoing coronary angiography publication-title: J Am Heart Assoc – volume: 12 start-page: 411 year: 2021 end-page: 425 article-title: Targeting the alternative bile acid synthetic pathway for metabolic diseases publication-title: Protein Cell – volume: 8 start-page: 159 year: 2018 article-title: Overview of bile acids signaling and perspective on the signal of Ursodeoxycholic acid, the most hydrophilic bile acid, in the heart publication-title: Biomolecules – volume: 36 year: 2018 article-title: TGR5 activation induces cytoprotective changes in the heart and improves myocardial adaptability to physiologic, inotropic, and pressure‐induced stress in mice publication-title: Cardiovasc Ther – volume: 385 start-page: 956 year: 2015 end-page: 965 article-title: Farnesoid X nuclear receptor ligand obeticholic acid for non‐cirrhotic, non‐alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo‐controlled trial publication-title: Lancet – volume: 12 start-page: 386 year: 2023 end-page: 403 article-title: An international Delphi consensus statement on metabolic dysfunction‐associated fatty liver disease and risk of chronic kidney disease publication-title: Hepatobiliary Surg Nutr – volume: 33 start-page: 791 year: 2021 end-page: 803.e7 article-title: Hyocholic acid species improve glucose homeostasis through a distinct TGR5 and FXR signaling mechanism publication-title: Cell Metab – volume: 64 start-page: 73 year: 2016 end-page: 84 article-title: Global epidemiology of nonalcoholic fatty liver disease‐meta‐analytic assessment of prevalence, incidence, and outcomes publication-title: Hepatology – volume: 11 start-page: 442 year: 2023 article-title: The interaction of gut microbiota and heart failure with preserved ejection fraction: from mechanism to potential therapies publication-title: Biomedicine – volume: 10 year: 2021 article-title: Nonalcoholic fatty liver disease and risk of heart failure among Medicare beneficiaries publication-title: J Am Heart Assoc – volume: 1864 start-page: 1345 year: 2018 end-page: 1355 article-title: Heart and bile acids–clinical consequences of altered bile acid metabolism publication-title: Biochim Biophys Acta Mol Basis Dis – volume: 145 start-page: e895 year: 2022 end-page: e1032 article-title: 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines publication-title: Circulation – volume: 25 start-page: 151 year: 2023 end-page: 162 article-title: Mechanisms linking metabolic‐associated fatty liver disease (MAFLD) to cardiovascular disease publication-title: Curr Hypertens Rep – volume: 14 start-page: 261 year: 2023 end-page: 282 article-title: The role of bile acids in cardiovascular diseases: from mechanisms to clinical implications publication-title: Aging Dis – volume: 45 start-page: 944 year: 2016 article-title: Bile acids control inflammation and metabolic disorder through inhibition of NLRP3 inflammasome publication-title: Immunity – volume: 11 start-page: 442 year: 2023 ident: e_1_2_10_35_1 article-title: The interaction of gut microbiota and heart failure with preserved ejection fraction: from mechanism to potential therapies publication-title: Biomedicine – ident: e_1_2_10_20_1 doi: 10.1007/s13238-020-00804-9 – ident: e_1_2_10_25_1 doi: 10.1002/ejhf.2333 – ident: e_1_2_10_28_1 doi: 10.1016/j.bbadis.2017.12.039 – ident: e_1_2_10_34_1 doi: 10.1016/j.cmet.2020.11.017 – ident: e_1_2_10_7_1 doi: 10.1007/s12072-023-10543-8 – ident: e_1_2_10_13_1 doi: 10.1161/JAHA.121.021654 – ident: e_1_2_10_19_1 doi: 10.1002/hep.28707 – ident: e_1_2_10_31_1 doi: 10.1111/1755-5922.12462 – volume: 29 start-page: S1043 year: 2024 ident: e_1_2_10_4_1 article-title: Current status and future trends of the global burden of MASLD publication-title: Trends Endocrinol Metab – ident: e_1_2_10_23_1 doi: 10.1016/j.cardfail.2017.06.007 – ident: e_1_2_10_2_1 doi: 10.1002/hep.28431 – ident: e_1_2_10_30_1 doi: 10.3390/antiox11091822 – ident: e_1_2_10_22_1 doi: 10.1016/S0140-6736(14)61933-4 – ident: e_1_2_10_27_1 doi: 10.3390/biom8040159 – ident: e_1_2_10_33_1 doi: 10.1002/hep.28890 – ident: e_1_2_10_24_1 doi: 10.1111/jgh.14894 – ident: e_1_2_10_5_1 doi: 10.1111/dom.15014 – ident: e_1_2_10_29_1 doi: 10.1002/cbf.3303 – ident: e_1_2_10_32_1 doi: 10.1016/j.immuni.2016.10.009 – volume: 13 year: 2024 ident: e_1_2_10_16_1 article-title: High‐sensitivity C‐reactive protein is associated with heart failure hospitalization in patients with metabolic dysfunction‐associated fatty liver disease and normal left ventricular ejection fraction undergoing coronary angiography publication-title: J Am Heart Assoc doi: 10.1161/JAHA.123.032997 – ident: e_1_2_10_6_1 doi: 10.1111/dom.15016 – volume: 14 start-page: 261 year: 2023 ident: e_1_2_10_26_1 article-title: The role of bile acids in cardiovascular diseases: from mechanisms to clinical implications publication-title: Aging Dis – ident: e_1_2_10_3_1 doi: 10.1038/s41575-023-00846-4 – ident: e_1_2_10_15_1 doi: 10.1007/s11906-023-01242-8 – volume: 145 start-page: e895 year: 2022 ident: e_1_2_10_9_1 article-title: 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines publication-title: Circulation – ident: e_1_2_10_11_1 doi: 10.1016/j.jacc.2021.11.007 – ident: e_1_2_10_10_1 doi: 10.1016/j.scib.2024.01.006 – ident: e_1_2_10_18_1 doi: 10.1161/JAHA.119.014279 – ident: e_1_2_10_14_1 doi: 10.1186/s12933-022-01697-0 – ident: e_1_2_10_12_1 doi: 10.1007/s00392-023-02371-5 – ident: e_1_2_10_17_1 doi: 10.1097/HJH.0000000000002716 – ident: e_1_2_10_8_1 doi: 10.21037/hbsn-22-421 – ident: e_1_2_10_21_1 doi: 10.1038/s41586-019-1865-0 |
SSID | ssj0004387 |
Score | 2.4709132 |
Snippet | Aim
To analyse the association between serum bile acid (BA) profile and heart failure (HF) with preserved ejection fraction (HFpEF) in patients with metabolic... To analyse the association between serum bile acid (BA) profile and heart failure (HF) with preserved ejection fraction (HFpEF) in patients with metabolic... AimTo analyse the association between serum bile acid (BA) profile and heart failure (HF) with preserved ejection fraction (HFpEF) in patients with metabolic... |
SourceID | proquest pubmed crossref wiley |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 3684 |
SubjectTerms | Acids bile acids profile Biopsy Congestive heart failure Echocardiography Ejection fraction Fatty liver Heart diseases Heart failure heart failure with preserved ejection fraction Liquid chromatography Liver diseases Mass spectroscopy metabolic dysfunction‐associated fatty liver disease Metabolism Serum levels Tauroursodeoxycholic acid Ursodeoxycholic acid Ventricle |
Title | Serum bile acid profiles are associated with heart failure with preserved ejection fraction in patients with metabolic dysfunction‐associated fatty liver disease: An exploratory study |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fdom.15709 https://www.ncbi.nlm.nih.gov/pubmed/38874096 https://www.proquest.com/docview/3087918836 https://www.proquest.com/docview/3068751516 |
Volume | 26 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NTtwwELYQh4pLC6U_29JqqDhwyWodb8KGnlBbhJC2laoicagU-VdauputNtkDnHgEXofX6ZN0xnZSoEWquFn2JE7kGXvG_vwNYzsqc8bwgU5GgmOAYqxNVGp4wp0nNOPCeZ7t8ef86GR4fJqdrrD37V2YwA_RbbiRZfj5mgxcqvqGkZv5rM-zPX95j7Ba5BB9_UMdNRQ-OR5OBGjxBaF41lsUT_fk7bXoLwfztr_qF5zDJ-x7-6kBZ_Kjv2xUX1_cYXF84L-ss8fREYWDoDkbbMVWT9mjcTxq32TXOIssZ6DwfSD1xEDM7l2DXGBNHFVrgHZygfJiN-DkhFDuoYoQtgSnNGDPPN6rArcI1yhgUkEkdK2D8Mw2qI3TiQZzXtNaS2K_Lq9u9ONk05zDlHAkEI-V9uGgAutRhB4sAJ4s9xk7Ofz07cNREvM8JFpkokhE6gidk2puUqMxPM4MRYXK5VIP7IDrFJWm0HvoHTpppbC5ks4K7rTEkknFc7ZazSv7koFznELIocHCUA6cUiKzWW5xqpKZyU2P7bYjXupIgk65OKZlGwzhUJR-KHrsXSf6MzB__Etoq1WbMhp_XRLJYsFHI5H32HbXjGZLZzGysvMlyeQYKaK7hTIvgrp1vYgR5UkssGXXK8393Zcfv4x94dX_i75mayk6ZgEnt8VWm8XSvkHHqlFvvQX9BtsiJNI |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NbtQwELaqVgIutPyVhQID4tBLVut4k24qLhWlWqBbJNRKvaDIv9LCbhbtZg_lxCPwOn2dPklnbCe0_EiIm2VP4kSesWfsz98w9lJlzhje08lAcAxQjLWJSg1PuPOEZlw4z7M9OsqHJ_13p9npCnvV3IUJ_BDthhtZhp-vycBpQ_qKlZvZtMuzHbq9t0YZvYk5f__jT_KovvDp8XAqQJsvCMez0eB42kevr0a_uZjXPVa_5Byss0_NxwakyZfuslZd_e0XHsf__ZsNdjv6orAXlOcOW7HVXXZjFE_b77FznEiWU1D4QpB6bCAm-F6AnGNNHFhrgDZzgVJj1-DkmIDuoYpAtoSoNGA_e8hXBW4eblLAuILI6boIwlNbo0JOxhrM2YKWWxK7-P7jSj9O1vUZTAhKAvFkaRf2KrAeSOjxAuD5cu-zk4M3x6-HSUz1kGiRiSIRqSOATqq5SY3GCDkzFBgql0vdsz2uU9SbQu-gg-iklcLmSjoruNMSSyYVD9hqNavsQwbOcYoi-wYLfdlzSonMZrnF2UpmJjcdtt0MeakjDzql45iUTTyEQ1H6oeiwF63o10D-8SehrUZvymj_i5J4Fgs-GIi8w563zWi5dBwjKztbkkyOwSJ6XCizGfSt7UUMKFVigS3bXmv-3n25_2HkC4_-XfQZuzk8Hh2Wh2-P3j9mt1L00wJsbout1vOlfYJ-Vq2eenO6BPmnKO4 |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELaqIlVcoOXVhRYGxKGXrOI4STf0VLGsymMLQlTqASnyU1rYzVa72UM58RP4O_07_BJm7CS0PCTEzbIncSLP2DP2528Ye6oyZwyPdTQQHAMUY22kEsMj7jyhGRfO82yPj_Ojk_TVaXa6xg7auzCBH6LbcCPL8PM1GfiZcZeM3MxnfZ7t0-W9a2keF5S3Yfj-J3dUKnx2PJwJ0OQLgvFstjCe7tGri9FvHuZVh9WvOKOb7GP7rQFo8rm_qlVff_mFxvE_f2aT3Wg8UTgMqrPF1mx1i22Mm7P22-wCp5HVDBS-D6SeGGjSey9BLrCmGVZrgLZygRJj1-DkhGDuoYogtoSnNGA_ecBXBW4R7lHApIKG0XUZhGe2RnWcTjSY8yUttiT2_eu3S_04WdfnMCUgCTTnSs_gsALrYYQeLQCeLfcOOxm9-PD8KGoSPURaZKKIROIInpNobhKjMT7ODIWFyuVSxzbmOkGtKfQ-uodOWilsrqSzgjstsWQScZetV_PKbjNwjlMMmRospDJ2SonMZrnFuUpmJjc9tteOeKkbFnRKxjEt22gIh6L0Q9FjTzrRs0D98SehnVZtysb6lyWxLBZ8MBB5jz3umtFu6TBGVna-IpkcQ0X0t1DmXlC3rhcxoESJBbbseaX5e_fl8O3YF-7_u-gjtvFuOCrfvDx-_YBdT9BJC5i5HbZeL1Z2F52sWj30xvQDc2InnQ |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Serum+bile+acid+profiles+are+associated+with+heart+failure+with+preserved+ejection+fraction+in+patients+with+metabolic+dysfunction%E2%80%90associated+fatty+liver+disease%3A+An+exploratory+study&rft.jtitle=Diabetes%2C+obesity+%26+metabolism&rft.au=Zhou%2C+Xiao%E2%80%90Dong&rft.au=Xu%2C+Cui%E2%80%90Fang&rft.au=Chen%2C+Qin%E2%80%90Fen&rft.au=Shapiro%2C+Michael+D.&rft.date=2024-09-01&rft.issn=1462-8902&rft.eissn=1463-1326&rft.volume=26&rft.issue=9&rft.spage=3684&rft.epage=3695&rft_id=info:doi/10.1111%2Fdom.15709&rft.externalDBID=n%2Fa&rft.externalDocID=10_1111_dom_15709 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1462-8902&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1462-8902&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1462-8902&client=summon |